Back to search

France· FR:68956396

MITOMYCINE ACCORD 10 mg, poudre pour solution injectable / perfusion ou voie intravésicale

A mitomycin product containing mitomycine, registered in France by ACCORD HEALTHCARE FRANCE. The same ATC class is registered in 17 of our 19 countries.

ATC L01DC03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedMITOMYCINE ACCORD 10 mg, poudre pour …ATCL01DC03REGISTER NO.FR:68956396PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Mitomycin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01DC03 (mitomycin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose

Mitomycin · ATC L01DC03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mitomycin costs, country by country.

Normalised to the WHO defined daily dose (4.29 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mitomycin · price per daily dose (4.29 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$32.20
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
MITOMYCINE
Manufacturer
ACCORD HEALTHCARE FRANCE
Country
France (FR)
ATC code
L01DC03
ATC class
Mitomycin
Defined daily dose
4.29 mg, intravesikal
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955040354
    1 flacon(s) en verre de 10 mg

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

193 interactions on record for mitomycin.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Mitomycin · interactions on record

193 records

  • 31 severe
  • 101 moderate
  • 15 minor
  • 46 info

Most severe, free to view

  • CladribineL01BB04severe
  • FluorouracilL01BC02severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mitomycin in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mitomycin products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Mitomycin Medac
  • Belgium · Mitomycin Accord Healthcare, Mitomycin Medac
  • Bulgaria · Митомицин Акорд
  • Cyprus · Mitomycin Accord, Mitomycine Substipharm
  • Czechia · Mitomycin Accord, Mitomycin Medac
  • Germany · Mitem, Mito-Apogepha
  • Denmark · Mitomycin Medac
  • Estonia · Mitomycin Accord, Mitomycin Medac
  • Spain · Mitomicina Accord, Mitomicina Aurovitas
  • Finland · Mitomycin Accord, Mitomycin Medac
  • United Kingdom (Northern Ireland) · Mitocin, Mitomycin Accord Healthcare
  • Ireland · Mitomycin Medac
  • Iceland · Mitomycin Medac
  • Italy · Mitomicina Accord, Mitomicina Medac
  • Lithuania · Mitomycin Medac
  • Latvia · Mitomycin Medac
  • Malta · Mitomycine Substipharm
  • Netherlands · Mitomycine Accord, Mitomycine Medac
  • Norway · Mitomycin Medac, Mitomycin Substipharm
  • Poland · Mitomycin Accord
  • Portugal · Mitomicina Accord, Mitomicina Accord Healthcare
  • Romania · Mitomicină Accord
  • Sweden · Mitomycin Medac, Mitomycin Substipharm
  • Slovenia · Mitomicin Accord, Mitomicin Medac
  • Slovakia · Mitomycin Accord, Mitomycin Medac

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eabab3d5-34a3-40e9-99df-d4bf061b9f06
GET /v1/drugs/eabab3d5-34a3-40e9-99df-d4bf061b9f06?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "68956396",
  "date_amm": "2017-12-01",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "MITOMYCINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution injectable pour perfusion ou",
  "voies_administration": "intraveineuse;intravésicale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about mitomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.